Assessing the Health Economic Outcomes from Commercially Insured Relapsing Multiple Sclerosis Patients Who Switched from Other Disease-Modifying Therapies to Teriflunomide, in the United States

OBJECTIVE: Assess patient characteristics, healthcare resource utilization (HCRU), and relapses in patients with multiple sclerosis (MS) who switched to teriflunomide from other disease-modifying therapies (DMTs). METHODS: Retrospective study of US Merative™ MarketScan(®) claims database (Jan 1, 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Araujo, Lita, Kyatham, Srikanth, Bzdek, Kristen G, Higuchi, Keiko, Greene, Nupur
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208242/
https://www.ncbi.nlm.nih.gov/pubmed/37234086
http://dx.doi.org/10.2147/CEOR.S401687

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10208242/
https://www.ncbi.nlm.nih.gov/pubmed/37234086
http://dx.doi.org/10.2147/CEOR.S401687

Ejemplares similares